Taken together with the previously demonstrated antitumor activity of this agent as well as anti-angiogenic effects demonstrated in this study, we believe that the STAT3 decoy oligonucleotide represents a promising single agent approach to targeting both the tumor and vascular compartments in various malignancies. Here, STAT3 is linked to neoplasm.